Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 29;jiaa228.
doi: 10.1093/infdis/jiaa228. Online ahead of print.

Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients

Affiliations
Free PMC article

Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients

Qing-Lei Zeng et al. J Infect Dis. .
Free PMC article

Abstract

Currently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) has been reported in almost all countries globally, and no effective therapy has been documented for COVID-19 and the role of convalescent plasma therapy is unknown. In current study, 6 COVID-19 subjects with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding, all tested negative for SARS-CoV-2 RNA by 3 days after infusion, and 5 died eventually. In conclusion, convalescent plasma treatment can discontinue SARS-CoV-2 shedding but cannot reduce mortality in critically end-stage COVID-19 patients, and treatment should be initiated earlier.

Keywords: Convalescent plasma therapy; Coronavirus disease 2019 (COVID-19); Fatality; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Survival rate; Viral shedding.

Similar articles

See all similar articles

Cited by 1 article

Feedback